Stocks Comparison
Glass House Brands vs Usana Health Sciences: revenue, profit, margins and growth compared
Glass House Brands brought in $182M of revenue in fiscal 2025, Usana Health Sciences $925.3M in fiscal 2025. Revenue changed by -9.4% at Glass House Brands and +8.3% at Usana Health Sciences on the year before, so Usana Health Sciences grew faster. Glass House Brands kept -16.3% of its revenue as net profit, Usana Health Sciences 1.2%. Free cash flow was -$15.7M at Glass House Brands and $8.5M at Usana Health Sciences.
Side by side, latest fiscal year
| GLAS | USNA | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (January 3, 2026) |
| Revenue | $182M | $925.3M |
| Revenue growth | -9.4% | +8.3% |
| Net income | -$29.7M | $10.8M |
| Net margin | -16.3% | 1.2% |
| Free cash flow | -$15.7M | $8.5M |
| Free cash flow margin | -8.6% | 0.9% |
| Earnings per share (diluted) | -$0.55 | $0.58 |
| Cash | $23.4M | $158.4M |
| Debt | $68.7M | n/a |
| Price to earnings | n/a | 25.0 |
| Market value | $598.4M | $267.9M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #261 of 523 · Health care | #150 of 523 · Health care |
Over the years
Questions about Glass House Brands and Usana Health Sciences
Which is bigger by revenue, Glass House Brands or Usana Health Sciences?
Usana Health Sciences is bigger by revenue: $925.3M in fiscal 2025, against $182M for Glass House Brands in fiscal 2025.
Which keeps more of its revenue as profit, Glass House Brands or Usana Health Sciences?
Glass House Brands had a net margin of -16.3% in fiscal 2025; Usana Health Sciences had 1.2% in fiscal 2025.
Which grew revenue faster, Glass House Brands or Usana Health Sciences?
In their latest fiscal years revenue changed by -9.4% at Glass House Brands and +8.3% at Usana Health Sciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.